SCHEMBL21580243

SCHEMBL21580243

CC(C)(C)[Si](C)(C)O[C@](C)(CC(=O)O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.51
HIF1A Q16665 1/20 0.51
KCNN4 O15554 1/20 0.40
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 1/20 0.35
ALOX15 P16050 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
RET P07949 1/20 0.34
KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17582871 1.00 CYP2C19 (0.51) CYP2C19HIF1AKCNN4MAPTKMT2A
SCHEMBL17582794 1.00 CYP2C19 (0.51) CYP2C19HIF1AKCNN4MAPTKMT2A
SCHEMBL25332274 0.81 BLM (0.45) CYP2C19HIF1AALDH1A1ALOX15HDAC6
SCHEMBL25331977 0.81 BLM (0.45) CYP2C19HIF1AALDH1A1ALOX15HDAC6
SCHEMBL25331971 0.81 BLM (0.45) CYP2C19HIF1AALDH1A1ALOX15HDAC6
SCHEMBL21110640 0.80 MAPK1 (0.38) CYP2C19HIF1AKCNN4KMT2AALDH1A1
SCHEMBL25332552 0.72 NAAA (0.39) ALDH1A1
SCHEMBL22160044 0.71 MAPK1 (0.43) CYP2C19HIF1AKCNN4MAPTKMT2A
SCHEMBL929910 0.71 HMGCR (0.41) CYP2C19HIF1AALDH1A1CHRM1KDM4E
SCHEMBL7725823 0.71 KCNN4 (0.51) CYP2C19HIF1AKCNN4MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351559-B2 Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators BIOHAVEN THERAPEUTICS LTD. (VG) 2025-07-08 US disclosed
US-20240300903-A1 BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2024-09-12 US disclosed
EP-4289822-A2 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (US) 2023-12-13 EP disclosed
EP-3572405-B9 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2023-12-06 EP disclosed
US-11834418-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators BIOHAVEN THERAPEUTICS LTD. (VG) 2023-12-05 US disclosed
EP-3572405-B1 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2023-07-26 EP disclosed
US-20200062714-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2020-02-27 US disclosed
EP-3572405-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS Knopp Biosciences LLC (US) 2019-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834418-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KCNA7, KCNJ2, KCNK17 CYP2C19 2329/4885HIF1A 1898/4885KCNN4 49/4885
US-20240300903-A1 BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNK17, KCNK2 CYP2C19 2364/4885HIF1A 2159/4885KCNN4 56/4885
US-12351559-B2 Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators KCNA7, KCNJ2, KCNK17 CYP2C19 1747/4885HIF1A 1915/4885KCNN4 48/4885
US-20200062714-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNJ2, KCNK17 CYP2C19 2329/4885HIF1A 1898/4885KCNN4 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.